Figure 6.

Reduced tumor growth and increased numbers of CD4⁺ T cells in tumor-bearing mice treated with LTbR-Ig. Mice inoculated s.c. with 3 × 10⁵ B16/F10 melanoma cells were treated i.p. every three days with LTbR-Ig (100 μg/mouse) or isotype control. (A) Immunohistochemical LYVE-1, ER-TR7, PDPN, and DAPI staining of day 14 tumor sections is presented. (B) Quantitative RT-PCR analysis of PDPN mRNA obtained from tumor tissues at day 14. (C) Mean tumor volume (mm³) and standard deviation are presented. (D) Representative PET/CT images, mean and standard deviation of total lesion glycolysis (TLG) of mice 13–14 d following tumor inoculation are denoted. SUV stands for standardized uptake value. (E) FACS plots and graphs represent gating strategy, mean percentages, and standard deviation of CD4⁺ T cells and CD4⁺ Foxp3⁺ T cells in tdLNs and CD45⁺CD4⁺ T cells in TILs 14–15 d after tumor inoculation. Data are representative of three independent experiments with 5–8 replicates each. Numbers on FACS plots denote frequency of gated population. *p < 0.05, **p < 0.005, ***p < 0.0005.